Annual report
4886.TEDINET S100TOTO
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 96
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥62.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥60.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥6.5bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥5.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥6.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥9.9bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥7.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥90.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥87.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥83.3bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥28.8bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥32.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥61.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥54.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2022-03-31d | Cons. | Net assets |
| Cash and deposits | ¥13.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥16.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥3.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥266.51 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.08 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,186.1 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,928.14 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,734.8 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 68.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 13.0% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 762 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 747 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 777 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥3.7bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.4bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥658m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥603m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥717m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥603m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥591m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥682m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥43.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥41.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥41.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥565m | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥630m | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥42.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.9bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.7bn | at 2022-03-31d | Standalone | Net assets |
| Cash and deposits | ¥2.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥87.1 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.95 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.79 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥40 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,506.47 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,447.55 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,443.94 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 30,563,199 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 75 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 79 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 74 | at 2022-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 15 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥226m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥162m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥64m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥39m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥125m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥201m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥64m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥64m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥42.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.2bn |
| Animal Health Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥4m |
| Animal Health Businessreportable segment | employees | at 2024-03-31 | 34 pure |
| Animal Health Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | segment assets | at 2024-03-31 | ¥3.5bn |
| Animal Health Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥195m |
| Pharmaceutical Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.2bn |
| Pharmaceutical Businessreportable segment | employees | at 2024-03-31 | 627 pure |
| Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥56.0bn |
| Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥56.0bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2024-03-31 | ¥45.0bn |
| Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥7.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥2.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥62.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥62.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥64m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥48.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥7.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥298m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥220m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥77m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥6m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥481m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥77m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥77m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥43.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Animal Health Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4m |
| Animal Health Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | segment assets | at 2023-03-31 | ¥3.0bn |
| Animal Health Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥409m |
| Pharmaceutical Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥53.6bn |
| Pharmaceutical Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥53.6bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2023-03-31 | ¥40.1bn |
| Pharmaceutical Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥60.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥60.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥77m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥43.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥6.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,450
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 75 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.114 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 1.000 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.710 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.766 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.647 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 6687 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 6055 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 4093 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 2949 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 11.4 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 23.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 32.7 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 100.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 100.0 | |
| Research and development expenses research and development activities | CurrentYearDuration | 4728000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 1545000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 30563199 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 30563199 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 30563199 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 30563199 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 20 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 24 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 55 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 108 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 4 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 5626 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 5837 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 90945 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 7933 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 71825 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 54917 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 11 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 79790 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 305421 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 21099 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.2978 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0260 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.2352 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.1798 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0000 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.2612 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 3050000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.1076 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 2204000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0778 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |